Giant cell arteritis. Part II. Treatment
Treatment options for giant cell arteritis (GCA) and its complications are considered. GCA is treatable with glucocorticoids (GC). The data available in the literature suggest that it is necessary to hospitalize GCA patients with acute vision loss or brain ischemia to administer intravenous megadose...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2012-12-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/447 |
| id |
doaj-1af05a192520478a94778793134284ac |
|---|---|
| record_format |
Article |
| spelling |
doaj-1af05a192520478a94778793134284ac2021-07-29T09:00:08ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2012-12-0164495410.14412/1996-7012-2012-7621752Giant cell arteritis. Part II. TreatmentAzamat Makhmudovich SatybaldyevTreatment options for giant cell arteritis (GCA) and its complications are considered. GCA is treatable with glucocorticoids (GC). The data available in the literature suggest that it is necessary to hospitalize GCA patients with acute vision loss or brain ischemia to administer intravenous megadose methylprednisolone and to control and prevent complications of GC therapy. It is expedient to use aspirin in these cases. The evidence for the use of methotrexate and other disease-modifying antirheumatic and genetically engineered drugs as GC-saving drugs is discussed.https://mrj.ima-press.net/mrj/article/view/447giant cell arteritistreatmentglucocorticoidsmethotrexategenetically engineered drugs |
| collection |
DOAJ |
| language |
Russian |
| format |
Article |
| sources |
DOAJ |
| author |
Azamat Makhmudovich Satybaldyev |
| spellingShingle |
Azamat Makhmudovich Satybaldyev Giant cell arteritis. Part II. Treatment Современная ревматология giant cell arteritis treatment glucocorticoids methotrexate genetically engineered drugs |
| author_facet |
Azamat Makhmudovich Satybaldyev |
| author_sort |
Azamat Makhmudovich Satybaldyev |
| title |
Giant cell arteritis. Part II. Treatment |
| title_short |
Giant cell arteritis. Part II. Treatment |
| title_full |
Giant cell arteritis. Part II. Treatment |
| title_fullStr |
Giant cell arteritis. Part II. Treatment |
| title_full_unstemmed |
Giant cell arteritis. Part II. Treatment |
| title_sort |
giant cell arteritis. part ii. treatment |
| publisher |
IMA-PRESS LLC |
| series |
Современная ревматология |
| issn |
1996-7012 2310-158X |
| publishDate |
2012-12-01 |
| description |
Treatment options for giant cell arteritis (GCA) and its complications are considered. GCA is treatable with glucocorticoids (GC). The data available in the literature suggest that it is necessary to hospitalize GCA patients with acute vision loss or brain ischemia to administer intravenous megadose methylprednisolone and to control and prevent complications of GC therapy. It is expedient to use aspirin in these cases. The evidence for the use of methotrexate and other disease-modifying antirheumatic and genetically engineered drugs as GC-saving drugs is discussed. |
| topic |
giant cell arteritis treatment glucocorticoids methotrexate genetically engineered drugs |
| url |
https://mrj.ima-press.net/mrj/article/view/447 |
| work_keys_str_mv |
AT azamatmakhmudovichsatybaldyev giantcellarteritispartiitreatment |
| _version_ |
1721250348281102336 |